Shared Decision Making to Improve Goals-of-Care Decisions for Families of Severe Acute Brain Injury Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale Medical School/Yale New Haven Medical Center
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Medical School
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥18 years of age; no upper age limit
- Documented health care proxy or legal next of kin of admitted SABI patient with traumatic brain injury, intracerebral hemorrhage or acute ischemic stroke.
- ≥3 days after insult ("stabilization period"); clinical team may ask study team to wait longer if clinically indicated
- SABI patient remains "critically ill" after 3 days defined as: either intubated and mechanically ventilated, or unable to swallow, needing feeding tube beyond hospital discharge (even if not intubated)
- Surrogate is physically present in ICU to receive decision aid and participate in planned family meeting in person (not over phone)
Exclusion Criteria:
- Devastating SABI near death
- Patient will be extubated and pass swallow evaluation (as deemed by clinical team)
- Surrogate is non-English speaking and no interpreter available to translate decision aid (no available validated, translated decision aid version)
- Surrogate is illiterate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
NO_INTERVENTION: Usual Care (n=20)
Control: general information about TBI from Center for Disease Control (CDC)/about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
|
|
|
EXPERIMENTAL: Decision Aid (n=20)
Paper Decision aid (share decision making tool) with worksheet for surrogates
|
Shared-decision making tool
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment
Time Frame: From date of approaching surrogate decision maker for consent until the date of the first documented goals-of-care family meeting, assessed up to 1 month after admission.
|
Consent rate
|
From date of approaching surrogate decision maker for consent until the date of the first documented goals-of-care family meeting, assessed up to 1 month after admission.
|
|
Participation
Time Frame: 1-36 hours after family meeting
|
Proportion of participants who read decision aid and completed worksheet
|
1-36 hours after family meeting
|
|
Retention
Time Frame: 3 months
|
Number of participants who complete follow-up
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinician-surrogate concordance scale score
Time Frame: Baseline and 1-36 hours after family meeting
|
measures prognostic concordance between ICU clinicians and surrogates.
Participants from both groups will independently estimate numerically a SABI patient's 6-month survival and return to independence.
Concordance is calculated as the absolute value of the difference in prognosis between the surrogate and the clinician, and, therefore, can range from 0 (no concordance) to 100 (full concordance).
|
Baseline and 1-36 hours after family meeting
|
|
Decision Self-Efficacy Scale
Time Frame: 1-36 hours after family meeting
|
is a validated scale that measures self-confidence in making an informed choice using a 5-point Likert scale ranging from 0 (not at all confident) to 4 (very confident).
|
1-36 hours after family meeting
|
|
Decisional Conflict Scale
Time Frame: 1-36 hours after family meeting
|
is a validated scale that measures the personal perception of choosing an option and factors contributing to choice uncertainty.
It is a 16-item, 5-item Likert scale with sub-scores for uncertainty, feeling informed, values clarity, decision support and effective decision-making.
It ranges from 0 (strongly agree) to 4 (strongly disagree).
|
1-36 hours after family meeting
|
|
AIS/Intracerebral Hemorrhage (ICH)/Traumatic Brain Injury (TBI) knowledge test
Time Frame: Baseline and 1-36 hours after family meeting
|
Medical knowledge about the goals-of-care decision in SABI will be assessed using the medical knowledge test, which was adapted to 17 questions about goals-of-care and SABI, all of which are addressed in the decision aid.
The % correct will be calculated.
|
Baseline and 1-36 hours after family meeting
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline,1-36 hours after family meeting, and 3-months
|
is a 14-item, two-domain (depression, anxiety) instrument with reliability and validity among ICU surrogates, which is recommended by consensus guidelines for the prospective measurement of psychological distress among ICU surrogates.
Each of the 14 questions are scored between 0 (not at all) and 3 (most of the time), and summed up for a total HADS score, which ranges from 0 to 42, with higher scores indicating worse symptoms.
Total HADS 0-7 =normal, 8-10 borderline abnormal, 11-21=abnormal, indicating high anxiety and depression.
|
Baseline,1-36 hours after family meeting, and 3-months
|
|
Impact of Events Scale-revised
Time Frame: Baseline,1-36 hours after family meeting, and 3-months
|
is a is a validated 15-item instrument, measuring post-traumatic stress disorder (PTSD) symptoms.
Total score is the sum of all questions and ranges from 0 to 88, with higher scores indicating worse PTSD symptoms.
|
Baseline,1-36 hours after family meeting, and 3-months
|
|
Quality of Communications Scale
Time Frame: 1-36 hours after family meeting
|
is a is a validated 17-item patient-centered instrument widely used in the ICU to assess surrogates' satisfaction of clinician communication about treatments and understanding treatment decisions.
It ranges between 0 (poor) to 10 (absolutely perfect).
Total score is the sum of all questions and ranges from 0 to 100, with higher scores indicating better communication.
|
1-36 hours after family meeting
|
|
Patient-Perceived Centeredness of Care Scale
Time Frame: 1-36 hours after family meeting
|
is a is a validated 14-item, 4-point Likert scale based test.
Its version adapted to surrogates has shown responsiveness in a recent trial of a nurse-driven communication intervention for surrogates in the ICU.
It ranges between 1 (very well) to 4 (not at all), and median score is calculated from all questions.
Median scores range from 1 to 4, with lower scores indicating more patient- and family-centered care.
|
1-36 hours after family meeting
|
|
Cumulative duration of the goals-of-care family meetings
Time Frame: 1-36 hours after family meeting
|
Investigators will track the duration of each goals-of-care meeting.
At the patient's ICU discharge, investigators will sum up the cumulative duration of all goals-of-care meetings [minutes].
|
1-36 hours after family meeting
|
|
Total number of goals-of-care family meetings
Time Frame: 1-36 hours after family meeting
|
Investigators will sum up the total number of goals-of-care meetings at the patient's ICU discharge.
|
1-36 hours after family meeting
|
|
Patient's survival status
Time Frame: 3-months after goals of care decision
|
Investigators will record whether the patient is dead or alive.
|
3-months after goals of care decision
|
|
Patient's Glasgow Outcome Scale
Time Frame: 3-months after goals of care decision
|
The Glasgow Outcome Score (GOS) is a validated 5-point scale given to traumatic brain injury or other brain injury patients at some point in their recovery.
It is a very general assessment of the general functioning of the person who suffered a head injury or other neurological injury.
It ranges from 1-5 (higher scores indicating better functional status): 1=death, 2=Vegetative State, 3=Severely Disabled (conscious but the patient requires others for daily support due to disability), 4=Moderately Disabled (the patient is independent but disabled), 5=Good Recovery (the patient has resumed most normal activities but may have minor residual problems).
|
3-months after goals of care decision
|
|
Patient's modified Rankin Scale
Time Frame: 3-months after goals of care decision
|
is a validated scale that measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.
It ranges from 0 (no symptoms at all) to 6 (death).
|
3-months after goals of care decision
|
|
Surrogate Decision Regret Scale
Time Frame: 3-months after goals of care decision
|
is a validated scale that measures distress or remorse after a health care decision with high internal consistency.
It asks 5 questions and provides a 5-point Likert scale.
It ranges between 1 (strongly agree) to 5 (strongly disagree).
|
3-months after goals of care decision
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dr. Susanne Muehlschlegel, MD, MPH, University of Massachusetts, Worcester
Publications and helpful links
General Publications
- Quinn T, Moskowitz J, Khan MW, Shutter L, Goldberg R, Col N, Mazor KM, Muehlschlegel S. What Families Need and Physicians Deliver: Contrasting Communication Preferences Between Surrogate Decision-Makers and Physicians During Outcome Prognostication in Critically Ill TBI Patients. Neurocrit Care. 2017 Oct;27(2):154-162. doi: 10.1007/s12028-017-0427-2.
- Moskowitz J, Quinn T, Khan MW, Shutter L, Goldberg R, Col N, Mazor KM, Muehlschlegel S. Should We Use the IMPACT-Model for the Outcome Prognostication of TBI Patients? A Qualitative Study Assessing Physicians' Perceptions. MDM Policy Pract. 2018 Mar 26;3(1):2381468318757987. doi: 10.1177/2381468318757987. eCollection 2018 Jan-Jun.
- Muehlschlegel S, Shutter L, Col N, Goldberg R. Decision Aids and Shared Decision-Making in Neurocritical Care: An Unmet Need in Our NeuroICUs. Neurocrit Care. 2015 Aug;23(1):127-30. doi: 10.1007/s12028-014-0097-2.
- Cai X, Robinson J, Muehlschlegel S, White DB, Holloway RG, Sheth KN, Fraenkel L, Hwang DY. Patient Preferences and Surrogate Decision Making in Neuroscience Intensive Care Units. Neurocrit Care. 2015 Aug;23(1):131-41. doi: 10.1007/s12028-015-0149-2.
- Muehlschlegel S, Goostrey K, Flahive J, Zhang Q, Pach JJ, Hwang DY. A Pilot Randomized Clinical Trial of a Goals-of-Care Decision Aid for Surrogates of Severe Acute Brain Injury Patients. Neurology. 2022 Jul 19;99(14):e1446-55. doi: 10.1212/WNL.0000000000200937. Online ahead of print.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Stroke
- Intracranial Hemorrhages
- Ischemic Stroke
- Brain Injuries
- Wounds and Injuries
- Hemorrhage
- Brain Injuries, Traumatic
- Cerebral Hemorrhage
Other Study ID Numbers
Other Study ID Numbers
- H00004724/H00015764
- 5K23HD080971 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.